Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP844500.RASkz1h8niUHHY0_teKVcj3IOfNvts7B7l30KLXI6VPEU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP844500.RASkz1h8niUHHY0_teKVcj3IOfNvts7B7l30KLXI6VPEU130_assertion type Assertion NP844500.RASkz1h8niUHHY0_teKVcj3IOfNvts7B7l30KLXI6VPEU130_head.
- NP844500.RASkz1h8niUHHY0_teKVcj3IOfNvts7B7l30KLXI6VPEU130_assertion description "[We selected ER-positive tumors, and clinical end points for the HOXB13-to-IL17BR ratio were disease-free survival (DFS) in patients with primary breast cancer (N = 619) and progression-free survival (PFS) in patients with recurrent breast cancer treated with first-line tamoxifen monotherapy (N = 193).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP844500.RASkz1h8niUHHY0_teKVcj3IOfNvts7B7l30KLXI6VPEU130_provenance.
- NP844500.RASkz1h8niUHHY0_teKVcj3IOfNvts7B7l30KLXI6VPEU130_assertion evidence source_evidence_literature NP844500.RASkz1h8niUHHY0_teKVcj3IOfNvts7B7l30KLXI6VPEU130_provenance.
- NP844500.RASkz1h8niUHHY0_teKVcj3IOfNvts7B7l30KLXI6VPEU130_assertion SIO_000772 17308270 NP844500.RASkz1h8niUHHY0_teKVcj3IOfNvts7B7l30KLXI6VPEU130_provenance.
- NP844500.RASkz1h8niUHHY0_teKVcj3IOfNvts7B7l30KLXI6VPEU130_assertion wasDerivedFrom befree-20150227 NP844500.RASkz1h8niUHHY0_teKVcj3IOfNvts7B7l30KLXI6VPEU130_provenance.
- NP844500.RASkz1h8niUHHY0_teKVcj3IOfNvts7B7l30KLXI6VPEU130_assertion wasGeneratedBy ECO_0000203 NP844500.RASkz1h8niUHHY0_teKVcj3IOfNvts7B7l30KLXI6VPEU130_provenance.